Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
Author:
L. Zygulska Aneta
Reference74 articles.
1. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opinion on Investigational Drugs. 2012;21:879-889. DOI: 10.1517/13543784.2012.684752
2. Crona DJ, Keisler MD, Walko CM. Regorafenib: A novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. The Annals of Pharmacotherapy. 2013;47:1685-1696. DOI: 10.1177/1060028013509792
3. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. DOI: 10.1016/S0140-6736(12)61900-X
4. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2015;16:619-629. DOI: 10.1016/S1470-2045(15)70156-7
5. Garcia-Alonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, et al. Single-agent regorafenib in metastatic colorectal cancer patients with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab (PREVIUM trial). The Oncologist. 2018;23:1271-e128. DOI: 10.1634/theoncologist.2018-0316